导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.70% | 914/4773 |
| 近一周 | -1.30% | 1987/5465 |
| 近一月 | -1.95% | 1393/5421 |
| 近一季 | -4.63% | 1857/5231 |
| 近半年 | 4.72% | 853/4920 |
| 近一年 | 13.23% | 901/4394 |
| 近两年 | 59.54% | 1252/2954 |
| 近三年 | 40.28% | 758/2253 |
| 成立以来 | 78.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.40% 1786/4961 |
18.00% 1431/5312 |
- - |
- - |
| 2025 | 19.59% 2204/4813 |
-0.24% 2141/3635 |
2.42% 1580/4076 |
14.35% 2921/4524 |
2.37% 976/4813 |
| 2024 | 16.50% 802/3463 |
3.40% 578/2808 |
-0.26% 720/3014 |
14.17% 2035/3129 |
-1.06% 1575/3463 |
| 2023 | -13.67% 1556/2656 |
1.16% 1626/2280 |
-4.61% 1222/2385 |
-3.84% 1001/2515 |
-6.97% 1998/2655 |
| 2022 | -20.62% 985/2207 |
-14.81% 1002/1919 |
7.97% 406/2016 |
-13.51% 913/2113 |
-0.22% 1576/2208 |
| 2021 | -4.84% 962/1822 |
-2.32% 619/1255 |
4.54% 874/1330 |
-8.75% 1154/1466 |
2.14% 688/1822 |
| 2020 | 46.65% 207/1250 |
-7.60% 556/1028 |
16.71% 420/1067 |
16.11% 168/1164 |
17.11% 138/1184 |
| 2019 | 47.40% 122/1092 |
26.60% 395/739 |
1.64% 115/788 |
5.18% 159/850 |
8.91% 273/918 |
| 2018 | - - |
- - |
- - |
0.12% 161/660 |
-12.68% 475/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发沪深300指数增强A VS. 长安沪深300非周期A(740101) |